摘要:
The present application provides an optical comb source in which the comb is produced by seeding a gain switched Fabry-Pérot laser with light from a single mode laser, while at the same time driving the Fabry-Pérot laser with a DC bias and RF signal.
摘要:
Microfluidic devices and in particular microfluidic devices incorporating a cascading valve arrangement for selectively controlling the flow of a fluid within the microfluidic device are described. Specific examples of a microfluidic device comprising a sacrificial valve (210) whose opening is triggered by the opening of a second valve (220), causing a retraction of a fluid spacer (213) thus bringing liquid (214) into contact with the dissolvable valve membrane (210).
摘要:
A system for sensing and measuring ammonia in a breath sample is described. The system includes a sampling means for capturing and directing a breath sample from a subject to an ammonia sensor, the ammonia sensor including a conducting polymer polyaniline sensor. The sampling means includes a breath sample capture chamber, the chamber having an inlet and outlet, the inlet having a first valve through which a breath is exhaled into the sample capture chamber, the outlet having a second valve through which breath surplus to the volume of the chamber is expelled, to provide capture of a breath sample of predefined volume.
摘要:
A method of monitoring a breast cancer patient's response to treatment, or of detecting recurrence of breast cancer, the method comprising a step of assaying a plurality of samples obtained from the patient over a period of time for expression levels of a plurality of biomarkers including Cancer Antigen 15-3 (CA 15-3) and one of either Glutamate or 12-Hydroxyeicosatetraenoic acid (12-HETE), and detecting a change in expression levels of CA 15-3 and one (or both) of either Glutamate or 12-HETE over the time period, wherein detection of a decreased expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a response to therapy and wherein detection of increased or stable expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a non-response to breast cancer therapy.